Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine
design, development and delivery, announced today that the company's
CEO, Dr. J. Joseph Kim, will present at Jesup & Lamont’s 2009 Growth
Stock & National Sales Conference to be held at the Waldorf Astoria Boca
Beach Club on July 30th in Boca Raton, Florida.
To register to attend the conference, contact Tammy Kraus at tkraus@jesuplamont.com.
Jesup & Lamont is a full service boutique brokerage and investment
banking firm based in New York City.
About Inovio Biomedical Corporation
Inovio Biomedical is engaged in the design, development, and delivery of
a new generation of vaccines, called DNA vaccines, focused on cancers
and infectious diseases. The company’s SynCon™ technology enables the
design of DNA-based vaccines capable of providing cross-protection
against new, unmatched strains of pathogens such as influenza. Inovio’s
proprietary electroporation-based DNA vaccine delivery technology has
been shown by initial human data to safely and significantly increase
gene expression and immune responses. Inovio’s clinical programs include
HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been
filed for an avian influenza vaccine. Partners and collaborators include
Merck, Tripep, University of Southampton, University of Pennsylvania,
and HIV Vaccines Trial Network. Inovio’s product candidates and
technologies are protected by an extensive global intellectual property
portfolio. More information is available at www.inovio.com.
This press release contains certain forward-looking statements
relating to our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines.
